Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application

Wei Yan; Naga Rajiv Lakkaniga; Francesca Carlomagno; Massimo Santoro; Neil Q. McDonald; Fengping Lv; Naresh Gunaganti; Brendan Frett; Hong Yu Li

doi:10.1021/acs.jmedchem.8b01092

Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application

Wei Yan, Naga Rajiv Lakkaniga, Francesca Carlomagno, Massimo Santoro, Neil Q. McDonald, Fengping Lv, Naresh Gunaganti, Brendan Frett, Hong Yu Li

Pharmacology and Toxicology

Research output: Contribution to journal › Review article › peer-review

62 Scopus citations

Abstract

The use of kinase-directed precision medicine has been heavily pursued since the discovery and development of imatinib. Annually, it is estimated that around 20000 new cases of tropomyosin receptor kinase (TRK) cancers are diagnosed, with the majority of cases exhibiting a TRK genomic rearrangement. In this Perspective, we discuss current development and clinical applications for TRK precision medicine by providing the following: (1) the biological background and significance of the TRK kinase family, (2) a compilation of known TRK inhibitors and analysis of their cocrystal structures, (3) an overview of TRK clinical trials, and (4) future perspectives for drug discovery and development of TRK inhibitors.

Original language	English (US)
Pages (from-to)	1731-1760
Number of pages	30
Journal	Journal of Medicinal Chemistry
Volume	62
Issue number	4
DOIs	https://doi.org/10.1021/acs.jmedchem.8b01092
State	Published - Feb 28 2019

ASJC Scopus subject areas

Molecular Medicine
Drug Discovery

Access to Document

10.1021/acs.jmedchem.8b01092

Cite this

@article{93b4d6e7b1a74adf987722f982b6a616,

title = "Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application",

abstract = "The use of kinase-directed precision medicine has been heavily pursued since the discovery and development of imatinib. Annually, it is estimated that around 20000 new cases of tropomyosin receptor kinase (TRK) cancers are diagnosed, with the majority of cases exhibiting a TRK genomic rearrangement. In this Perspective, we discuss current development and clinical applications for TRK precision medicine by providing the following: (1) the biological background and significance of the TRK kinase family, (2) a compilation of known TRK inhibitors and analysis of their cocrystal structures, (3) an overview of TRK clinical trials, and (4) future perspectives for drug discovery and development of TRK inhibitors.",

author = "Wei Yan and Lakkaniga, {Naga Rajiv} and Francesca Carlomagno and Massimo Santoro and McDonald, {Neil Q.} and Fengping Lv and Naresh Gunaganti and Brendan Frett and Li, {Hong Yu}",

note = "Publisher Copyright: {\textcopyright} 2018 American Chemical Society.",

year = "2019",

month = feb,

day = "28",

doi = "10.1021/acs.jmedchem.8b01092",

language = "English (US)",

volume = "62",

pages = "1731--1760",

journal = "Journal of Medicinal Chemistry",

issn = "0022-2623",

publisher = "American Chemical Society",

number = "4",

}

TY - JOUR

T1 - Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors

T2 - Development and Clinical Application

AU - Yan, Wei

AU - Lakkaniga, Naga Rajiv

AU - Carlomagno, Francesca

AU - Santoro, Massimo

AU - McDonald, Neil Q.

AU - Lv, Fengping

AU - Gunaganti, Naresh

AU - Frett, Brendan

AU - Li, Hong Yu

PY - 2019/2/28

Y1 - 2019/2/28

N2 - The use of kinase-directed precision medicine has been heavily pursued since the discovery and development of imatinib. Annually, it is estimated that around 20000 new cases of tropomyosin receptor kinase (TRK) cancers are diagnosed, with the majority of cases exhibiting a TRK genomic rearrangement. In this Perspective, we discuss current development and clinical applications for TRK precision medicine by providing the following: (1) the biological background and significance of the TRK kinase family, (2) a compilation of known TRK inhibitors and analysis of their cocrystal structures, (3) an overview of TRK clinical trials, and (4) future perspectives for drug discovery and development of TRK inhibitors.

AB - The use of kinase-directed precision medicine has been heavily pursued since the discovery and development of imatinib. Annually, it is estimated that around 20000 new cases of tropomyosin receptor kinase (TRK) cancers are diagnosed, with the majority of cases exhibiting a TRK genomic rearrangement. In this Perspective, we discuss current development and clinical applications for TRK precision medicine by providing the following: (1) the biological background and significance of the TRK kinase family, (2) a compilation of known TRK inhibitors and analysis of their cocrystal structures, (3) an overview of TRK clinical trials, and (4) future perspectives for drug discovery and development of TRK inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=85053832680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053832680&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.8b01092

DO - 10.1021/acs.jmedchem.8b01092

M3 - Review article

C2 - 30188734

AN - SCOPUS:85053832680

SN - 0022-2623

VL - 62

SP - 1731

EP - 1760

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

IS - 4

ER -

Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this